Pathogenesis of prion diseases: current status and future outlook
The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Abstract
The prion, a conformational variant of a host protein, is the infectious particle responsible for transmissible spongiform encephalopathy (TSE), a fatal neurodegenerative disease of humans and animals. The principal target of prion pathology is the brain, yet most TSEs also display prion replication at extra-cerebral locations, including secondary lymphoid organs and sites of chronic inflammation. Despite significant progress in our understanding of this infectious agent, many fundamental questions relating to the nature of the prion, including the mechanism of replication and the molecular events underlying brain damage, remain unanswered. Here we focus on the unresolved issues pertaining to prion pathogenesis, particularly on the role played by the immune system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prion diseases are caused in part (or at least accompanied by) the conversion of the prion protein PrP from its normal form PrPC to a conformationally distinct version PrPSc and that the latter can autocatalyse this conversion”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Aguzzi and Heikenwälder 2006
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“For example, unmethylated cytosine phosphate guanosine (CpG) motifs present in bacterial DNA can stimulate mouse and human immune responses through TLR9 (Ref”
BackgroundThe Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease
Hogg, J. C., Chu, F., Utokaparch, S., Woods, R., Elliott, W. M., Buzatu, L., Cherniack, R. M., Rogers, R. M., Sciurba, F. C., Coxson, H. O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032158 · Cited by 3,782 · cited 1×
“Many chronic inflammatory conditions, some of which are very common and include rheumatoid arthritis, type-I diabetes, Crohn's disease, Hashimoto's disease and chronic obstructive pulmonary disease, result in organized inflammatory foci of B lymphocytes, FDCs, DCs, macrophages and other immune cells associated with ge…”
BackgroundThe TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
A new variant of Creutzfeldt-Jakob disease in the UK
Will, R. G., Ironside, J. W., Zeidler, M., Estibeiro, K., Cousens, S. N., Smith, P. G., Alperovitch, A., Poser, S., Pocchiari, M., & Hofman, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91412-9 · Cited by 2,707 · cited 1×
“Over the same period, transmission of BSE to humans is believed to have caused over 150 cases of a new variant of CJD (vCJD”
BackgroundMice devoid of PrP are resistant to scrapie
Büeler, H., Aguzzi, A., Sailer, A., Greiner, R.-A., Autenried, P., Aguet, M., & Weissmann, C. (1993) · Cell · doi:10.1016/0092-8674(93)90360-3 · Cited by 2,100 · cited 1×
“However, brain infectivity is only detected after 4–5 months post-inoculatio”
BackgroundSelf-citationTargeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,041
Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD
Collinge, J., Sidle, K. C. L., Meads, J., Ironside, J., & Hill, A. F. (1996) · Nature · doi:10.1038/383685a0 · Cited by 1,735 · cited 1×
“Over the same period, transmission of BSE to humans is believed to have caused over 150 cases of a new variant of CJD (vCJD”
BackgroundNormal development and behaviour of mice lacking the neuronal cell-surface PrP protein
Büeler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H.-P., DeArmond, S. J., Prusiner, S. B., Aguet, M., & Weissmann, C. (1992) · Nature · doi:10.1038/356577a0 · Cited by 1,655 · cited 1×
“33 ) and Prnp knockout mice were first constructed in 1992 (Ref”
BackgroundSensitive detection of pathological prion protein by cyclic amplification of protein misfolding
Saborio, G. P., Permanne, B., & Soto, C. (2001) · Nature · doi:10.1038/35081095 · Cited by 1,310 · cited 1×
“Protein misfolding cyclic amplification (PMCA) is also a promising method for the sensitive detection of the pathological prion protei”
MethodNMR structure of the mouse prion protein domain PrP(121–231)
Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R., & Wüthrich, K. (1996) · Nature · doi:10.1038/382180a0 · Cited by 1,257 · cited 1×
“The carboxyl terminus of PrP C is stabilized by a disulfide bond that links helices two and thre”
Background
Cited by
Prions: Protein Aggregation and Infectious Diseases
Aguzzi, A., & Calella, A. M. (2009) · Physiological Reviews · doi:10.1152/physrev.00006.2009 · Cited by 504
Self-citationBellingham, S. A., Coleman, B. M., & Hill, A. F. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks832 · Cited by 440
“Prion diseases are characterized by a protracted asymptomatic pre-clinical period, whereby PrP continually propagates, prior to the rapid onset of dementia, neuronal loss, spongiform change and ultimately death [reviewed in (2)].”
BackgroundExosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases?
Bellingham, S. A., Guo, B. B., Coleman, B. M., & Hill, A. F. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00124 · Cited by 412
“However, all forms of the disease are transmissible, with possible routes of infection through dietary exposure, medical procedures, and blood transfusion (reviewed in Aguzzi and Heikenwalder, 2006).”
BackgroundKell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…com- pletely, are represented by the prion diseases, in particular the TSEs including bovine spongiform encephalopathy (BSE) (e.g. Aguzzi et al. 2008a; Aguzzi and Heikenwälder 2006; Caughey and Baron 2006; Caughey and Lansbury 2003; Linden et al. 2008) and scrapie (e.g. Bulgin and Melson 2007;…”
BackgroundMolecular Mechanisms of Prion Pathogenesis
Aguzzi, A., Sigurdson, C., & Heikenwaelder, M. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.154326 · Cited by 351
Self-citationImplications of peptide assemblies in amyloid diseases
Ke, P. C., Sani, M.-A., Ding, F., Kakinen, A., Javed, I., Separovic, F., Davis, T. P., & Mezzenga, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00372b · Cited by 338
Exosomes: Mediators of Neurodegeneration, Neuroprotection and Therapeutics
Kalani, A., Tyagi, A., & Tyagi, N. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8544-1 · Cited by 332
“Prion disease is caused by the abnormal form of the prion protein PrP which is a toxic scrapie confirmation of the normal prion protein PrP and eventually results in neuronal death causing large spongioform vacuoles in the brain tissue [74].”
BackgroundChemistry and biology of mammalian metallothioneins
Vašák, M., & Meloni, G. (2011) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-011-0799-2 · Cited by 268
Molecular and cellular aspects of protein misfolding and disease
Herczenik, E., & Gebbink, M. F. B. G. (2008) · The FASEB Journal · doi:10.1096/fj.07-099671 · Cited by 205
Genome-Wide Screen for Modifiers of Ataxin-3 Neurodegeneration in Drosophila
Bilen, J., & Bonini, N. M. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030177 · Cited by 196
“[7–9], indicating that these diseases may share molecular and”
BackgroundThe Prion Protein Knockout Mouse: A Phenotype Under Challenge
Steele, A. D., Lindquist, S., & Aguzzi, A. (2007) · Prion · doi:10.4161/pri.1.2.4346 · Cited by 157
“The model rests on the following assumptions: (1) PrP activates a hitherto unidentified receptor (PrPR) which transmits myelin maintenance signals (flashes); (2) in the absence of PrP, PrPR exerts some residual activity, either constitutively or by recruiting a surrogate ligand; (3) the activity of PrP and its mutants…”
BackgroundMethodSelf-citationPrion Diseases: From Protein to Cell Pathology
Kovács, G. G., & Budka, H. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070442 · Cited by 174
“Its up-regulation may occur in inflammatory conditions and may provide an increased substrate for PrP-PrP conversion.(2,19) Based on structural similarity, it has been proposed that PrP might function as a member of the Bcl-2 family of proteins.”
Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice
Clavaguera, F., Hench, J., Lavenir, I., Schweighauser, G., Frank, S., Goedert, M., & Tolnay, M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1231-5 · Cited by 143
“The replication of peripherally applied prions and their translocation to the brain are dependent on haematopoietic and stromal immune cells, together with the sympathetic innervation of abdominal lymphoid organs [1].”
BackgroundTrudler, D., Farfara, D., & Frenkel, D. (2010) · Mediators of Inflammation · doi:10.1155/2010/497987 · Cited by 118
“Furthermore, treatment with synthetic oligodeoxynucleotides that contain cytosine phosphate guanosine (CpG-ODN) motifs, known to bind to TLR9, have been suggested as possible treatment for prion diseases in a mouse model, by delaying the disease onset [105, 107].”
BackgroundPost-Translational Control of Protein Function by Disulfide Bond Cleavage
Cook, K. M., & Hogg, P. J. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4807 · Cited by 126
Brooks, P. J. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.03.016 · Cited by 135
“However, neuropathological studies have not detected amyloid accumulation in the brains of XP patients, nor is there any evidence of spongiform encephalopathy which is characteristic of prion diseases [69].”
BackgroundCytoplasmic dynein in neurodegeneration
Eschbach, J., & Dupuis, L. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.004 · Cited by 134
Stys, P. K., You, H., & Zamponi, G. W. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.225276 · Cited by 115
“The C-terminal half of the protein contains three α-helices and a glycophosphatidylinositol (GPI) anchor at position 231 that mediates an association with the extracellular leaflet of the plasma membrane (Aguzzi & Heikenwalder, 2006).”
BackgroundMammalian Metallothionein-3: New Functional and Structural Insights
Vašák, M., & Meloni, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061117 · Cited by 105
“In the pathogenesis of prion diseases, the structural conversion of a natively folded prion protein (PrPC) [73], into a misfolded (PrPSc) is the key molecular event [2,74].”
BackgroundNakagaki, T., Satoh, K., Ishibashi, D., Fuse, T., Sano, K., Kamatari, Y. O., Kuwata, K., Shigematsu, K., Iwamaru, Y., Takenouchi, T., et al. (2013) · Autophagy · doi:10.4161/auto.25381 · Cited by 110
“Increasing evidence suggests that inflammation processes such as gliosis are involved in the pathogenesis of prion diseases.(39) Table 1.”
BackgroundExosomes in neurologic and psychiatric disorders
Tsilioni, I., Panagiotidou, S., & Theoharides, T. C. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.05.005 · Cited by 93
“The major component of the infectious prion agent is an abnormal isoform of the cellular form of the prion protein (PrP) referred to as PrP and leads to neuronal death, causing large spongiform vacuoles in brain tissue.(42) Both PrP and PrP forms have been associated with exosomes, and PrP-containing exosomes have bee…”
BackgroundMonaco, A., & Fraldi, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00037 · Cited by 95
“Amyloid aggregates containing misfolded prion protein (PrP) cause the so-called prion diseases, a group of rare neurodegenerative conditions characterized by the capability of misfolded PrP to transmit their pathological shape onto normal variants of the same protein (Aguzzi and Heikenwalder, 2006).”
BackgroundPrincipia ætiologica: taking causality beyond Koch's postulates
Inglis, T. J. J. (2007) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47179-0 · Cited by 103
“Possibly the greatest challenge to any novel approach to causal analysis of infectious disease is the group of proposed infective agents that have been linked with the transmissible spongiform encephalopathies (Aguzzi & Heikenwalder, 2006).”
Santos, T. G., Silva, I. R., Costa‐Silva, B., Lepique, A. P., Martins, V. R., & Lopes, M. H. (2011) · Stem Cells · doi:10.1002/stem.664 · Cited by 93
Kim, C., Haldiman, T., Cohen, Y., Chen, W., Blevins, J. E., Sy, M., Cohen, M. L., & Safar, J. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002242 · Cited by 84
“Although remarkable progress has been made in understanding the structure of laboratory strains of rodent prions [2,10,18–20], knowledge of the molecular basis of human prion diseases has lagged behind.”
BackgroundAerosols Transmit Prions to Immunocompetent and Immunodeficient Mice
Haybaeck, J., Heikenwälder, M. F., Klevenz, B., Schwarz, P., Margalith, I., Bridel, C., Mertz, K. D., Zirdum, E., Petsch, B., Fuchs, T. J., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001257 · Cited by 75
“Prions, which are the cause of fatal neurodegenerative disorders termed transmissible spongiform encephalopa-thies (TSEs), can be experimentally or naturally transmitted via prion-contaminated food, blood, milk, saliva, feces and urine.”
InfluentialSelf-citationRetractedPrion protein and its ligand stress inducible protein 1 regulate astrocyte development
Arantes, C., Nomizo, R., Lopes, M. H., Hajj, G. N. M., Lima, F. R. S., & Martins, V. R. (2009) · Glia · doi:10.1002/glia.20861 · Cited by 75
“PrPC is a glycosylphosphatidylinositol (GPI)-anchored protein, which is highly expressed in the brain (Aguzzi and Heikenwalder, 2006; Prusiner et al., 1998).”
BackgroundToward Therapy of Human Prion Diseases
Aguzzi, A., Lakkaraju, A. K., & Frontzek, K. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052745 · Cited by 85
Self-citationThe role of calorie restriction and SIRT1 in prion-mediated neurodegeneration
Chen, D., Steele, A. D., Hutter, G., Bruno, J., Govindarajan, A., Easlon, E., Lin, S.-J., Aguzzi, A., Lindquist, S., & Guarente, L. (2008) · Experimental Gerontology · doi:10.1016/j.exger.2008.08.050 · Cited by 71
“The ongoing conversion of PrPC to PrPSc in neurons is required for prion toxicity (Brandner et al., 1996; Mallucci et al., 2003; Aguzzi and Heikenwalder, 2006).”
BackgroundSelf-citationRodent models for prion diseases
Groschup, M. H., & Buschmann, A. (2008) · Veterinary Research · doi:10.1051/vetres:2008008 · Cited by 83
“Various transgenic mouse models carrying mutations that affect their immune system have played an important role in elaborating today’s understanding of these events (for review see [1]).”
BackgroundChiocchetti, R., Mazzuoli, G., Albanese, V., Mazzoni, M., Clavenzani, P., Lalatta-Costerbosa, G., Lucchi, M. L., Di Guardo, G., Marruchella, G., & Furness, J. B. (2008) · Cell and Tissue Research · doi:10.1007/s00441-008-0583-y · Cited by 69
“Following oral ingestion or experimental introduction of prions protein into the intestinal lumen of sheep and other animals, PrP is soon observed (within hours or a few days) in epithelial M cells overlying PPs and in the PP themselves (Aguzzi and Polymenidou 2004; Aguzzi and Heikenwalder 2006; Mabbott and MacPherson…”
BackgroundRecent advances in biosensors for neurodegenerative disease detection
Ganesh, H. V. S., Chow, A. M., & Kerman, K. (2016) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2016.02.012 · Cited by 73
Singh, A., Mohan, M. L., Isaac, A. O., Luo, X., Petrák, J., Vyoral, D., & Singh, N. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004468 · Cited by 67
“and sporadic prion disorders, where a change in the conformation of PrP from a mainly a-helical to a b-sheet rich PrP-scrapie (PrP) form renders it infectious and pathogenic [1–5].”
BackgroundStudies on the Structural Stability of Rabbit Prion Probed by Molecular Dynamics Simulations
Zhang, J. (2009) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2009.10507305 · Cited by 66
“However, there is no effective therapeutic approach for treating all these diseases ([6, 8, 1]).”
BackgroundCheng, L., Zhao, W., & Hill, A. F. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.011 · Cited by 71
Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders
Neff, F., Wei, X., Noelker, C., Bacher, M., Du, Y., & Dodel, R. C. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.04.010 · Cited by 62
Lymphotoxin-Dependent Prion Replication in Inflammatory Stromal Cells of Granulomas
Heikenwälder, M. F., Kurrer, M. O., Margalith, I., Kranich, J., Zeller, N., Haybaeck, J., Polymenidou, M., Matter, M. S., Bremer, J., Jackson, W. S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.10.014 · Cited by 59
“Administration of soluble dimeric LTbR leads to the rapid disappearance of FDCs from spleen (Mackay and Browning, 1998) and was previously found to interfere with splenic prion replication (Aguzzi and Heikenwalder, 2006; Mabbott et al., 2000; Montrasio et al., 2000).”
BackgroundSelf-citationNew insights into cellular prion protein (PrPc) functions: The “ying and yang” of a relevant protein
Nicolás, O., Gavín, R., & del Río, J. A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.06.002 · Cited by 57
“…derived from PrPc knockout mice in vitro (Giri et al., 2006), and Prnp null mice are re-sensitized to prion infection even when several aminotruncated PrPc constructs are expressed (Aguzzi and Heikenwalder, 2006; Aguzzi and Polymenidou, 2004; Fischer et al., 1996; Flechsig et al., 2000).”
Ashok, A., & Hegde, R. S. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-01-0087 · Cited by 57
“Several dramatic examples of dominant gain-of-function disorders are caused by misfolding of PrP, a widely expressed cell surface glycoprotein of unknown function (Prusiner, 1998; Aguzzi and Heikenwalder, 2006; Wadsworth and Collinge, 2007).”
BackgroundPrions: Beyond a Single Protein
Das, A. S., & Zou, W. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-15 · Cited by 68
“neys, gastrointestinal tract, skin, and endothelium (35, 48, 49).”
Spinner, D. S., Kascsak, R. B., LaFauci, G., Meeker, H. C., Ye, X., Flory, M. J., Kim, J. I., Schuller-Levis, G. B., Levis, W. R., Wisniewski, T., et al. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1106665 · Cited by 54
Zhong, G., Wang, X., Li, J., Xie, Z., Wu, Q., Chen, J., Wang, Y., Chen, Z., Cao, X., Li, T., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231103085859 · Cited by 56
“PrP C has a series of physiological functions, such as immunoregulation [112], neuroprotection, antioxidant [113], signal transduction, and synaptic transmission [114].”
BackgroundCancellotti, E., Bradford, B. M., Tuzi, N. L., Hickey, R., Brown, D., Brown, K., Barron, R. M., Kisielewski, D., Piccardo, P., & Manson, J. C. (2010) · Journal of Virology · doi:10.1128/jvi.02374-09 · Cited by 52
The Structural Stability of Wild-type Horse Prion Protein
Zhang, J. (2011) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2011.10507391 · Cited by 52
Prion Pathogenesis is Independent of Caspase-12
Steele, A. D., Hetz, C., Yi, C., Jackson, W., Borkowski, A., Yuan, J., Wollmann, R. L., & Lindquist, S. (2007) · Prion · doi:10.4161/pri.1.4.5551 · Cited by 45
Mattei, V., Barenco, M. G., Tasciotti, V., Garofalo, T., Longo, A., Boller, K., Löwer, J., Misasi, R., Montrasio, F., & Sorice, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005057 · Cited by 43
“central nervous system are still not completely elucidated [3,4,5].”
BackgroundChoi, C. J., Anantharam, V., Martin, D. P., Nicholson, E. M., Richt, J. A., Kanthasamy, A., & Kanthasamy, A. G. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq049 · Cited by 48
“The major neurological symptoms are extrapyramidal motor signs, including tremors, ataxia, and myoclonus (Aguzzi and Heikenwalder, 2006; Johnson, 2005).”
BackgroundYamazaki, T., Blinov, N., Wishart, D. S., & Kovalenko, A. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.123000 · Cited by 50
“The fragment consists of five Ab(1-42) peptides (53).”
AA-Amyloidosis Can Be Transferred by Peripheral Blood Monocytes
Sponarova, J., Nyström, S. N., & Westermark, G. T. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003308 · Cited by 47
“In animal studies, AA-amyloidosis displays great similarity with transmissible spongiform encephalitis (TSE), because both diseases can be induced or accelerated by introduction of aggregates of misfolded proteins and can be transferred between subjects [13,18–22].”
BackgroundThe prion-like transmission of tau oligomers via exosomes
Jackson, N. A., Guerrero-Muñoz, M. J., & Castillo-Carranza, D. L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.974414 · Cited by 42
“Neurodegenerative prion diseases that afflict humans include Creutzfeldt-Jakob disease (CJD) and Gertsmann-Straussler-Scheinker syndrome (GSS) (Aguzzi and Heikenwalder, 2006).”
BackgroundA Structural Overview of the Vertebrate Prion Proteins
Pastore, A., & Zagari, A. (2007) · Prion · doi:10.4161/pri.1.3.5281 · Cited by 51
Acín, C., Bolea, R., Monzón, M., Monleón, E., Moreno, B., Filali, H., Marín, B., Sola, D., Betancor, M., Guijarro, I. M., et al. (2021) · Animals · doi:10.3390/ani11030691 · Cited by 46
The secret life of extracellular vesicles in metal homeostasis and neurodegeneration
Bellingham, S. A., Guo, B. B., & Hill, A. F. (2015) · Biology of the Cell · doi:10.1111/boc.201500030 · Cited by 51
“The C-terminal domain also contains two sites for N-linked glycosylation and a C-terminal signal peptide, which is replaced with the GPI anchor during biosynthesis (Aguzzi and Heikenwalder, 2006).”
BackgroundAggregate-Depleted Brain Fails to Induce Aβ Deposition in a Mouse Model of Alzheimer's Disease
Duran-Aniotz, C., Morales, R., Moreno-Gonzalez, I., Hu, P. P., Fedynyshyn, J., & Soto, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089014 · Cited by 43
“Despite the low incidence of prion diseases among human population, the unorthodox nature of the infectious agent [11], the potential of pre-symptomatic individuals to spread disease [12], and the risk of zoonotic transmission [13],”
BackgroundCurrent strategies to prevent transmission of prions by human plasma derivatives
Burnouf, T., & Padilla, A. (2006) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2006.11.001 · Cited by 48
Can misfolded proteins be beneficial? The HAMLET case
Pettersson-Kastberg, J., Aits, S., Gustafsson, L., Mossberg, A., Storm, P., Trulsson, M., Persson, F., Mok, K. H., & Svanborg, C. (2009) · Annals of Medicine · doi:10.1080/07853890802502614 · Cited by 48
Strain-dependent profile of misfolded prion protein aggregates
Morales, R., Hu, P. P., Duran-Aniotz, C. A., Moda, F., Díaz‐Espinoza, R., Chen, B., Bravo-Alegria, J. B., Makarava, N., Baskakov, I. V., & Soto, C. A. (2016) · Scientific Reports · doi:10.1038/srep20526 · Cited by 46
Prion proteins: Physiological functions and role in neurological disorders
Hu, W., Kieseier, B. C., Frohman, E. M., Eagar, T. N., Rosenberg, R. N., Hartung, H.-P., & Stüve, O. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.06.019 · Cited by 49
“The propagation of PrP has been associated with central nervous system (CNS) lesions characterized by astrocyte proliferation, microglial activation, and spongiform vacuolation [3,10].”
BackgroundDirect Detection of Soil-Bound Prions
Genovesi, S., Leita, L., Sequi, P., Andrighetto, I., Sorgato, M. C., & Bertoli, A. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001069 · Cited by 40
“In this case, one cannot exclude that the presence of inflammogenic pathogens in the inoculum stimulates PrP expression [35] and, consequently, PrP accumulation.”
BackgroundZhang, J. (2010) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2010.10.020 · Cited by 36
“However, for treating all these diseases, there is no effective therapeutic approach (Aguzzi and Heikenwalder, 2006; Prusiner, 1998; Weissmann, 2004).”
BackgroundMolecular Dynamics Studies on the Structural Stability of Wild-type Dog Prion Protein
Zhang, J., & Liu, D. D. W. (2011) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2011.10508613 · Cited by 36
Zhang, J. (2010) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2010.01.024 · Cited by 36
“However, there is no effective therapeutic approach for treating all these diseases (Aguzzi and Heikenwalder, 2006; Prusiner, 1998; Weissmann, 2004).”
BackgroundPrion interference with multiple prion isolates
Schutt, C. R., & Bartz, J. C. (2008) · Prion · doi:10.4161/pri.2.2.6806 · Cited by 35
Brown, P. (2008) · Neurology · doi:10.1212/01.wnl.0000302186.10596.f6 · Cited by 41
Steele, A. D., King, O., Jackson, W., Hetz, C., Borkowski, A., Thielen, P., Wollmann, R. L., & Lindquist, S. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3290-07.2007 · Cited by 33
“Prion infections cause characteristic lesions in the brain: spongiform vacuolation, aggregates of PrP, activation of microglia, proliferation of astrocytes, and ultimately loss of neurons (Aguzzi and Heikenwalder, 2006).”
BackgroundInfluentialTherapy for prion diseases: Insights from the use of RNA interference
White, M. D., & Mallucci, G. R. (2009) · Prion · doi:10.4161/pri.3.3.9289 · Cited by 37
CD36 Participates in PrP106–126-Induced Activation of Microglia
Kouadir, M., Yang, L., Tan, R., Shi, F., Lu, Y., Zhang, S., Yin, X., Zhou, X., & Zhao, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030756 · Cited by 34
“In prion diseases and other neurodegenerative disorders, microglia can become overactivated and release ROS, NO, and cytokines, which might cause vascular damage in addition to neurodegeneration [7,8,9,10].”
Infectious Alzheimer's disease?
Riek, R. (2006) · Nature · doi:10.1038/444429a · Cited by 35
High levels of Cellular Prion Protein improve astrocyte development
Hartmann, C. A., Martins, V. R., & Lima, F. R. S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.11.032 · Cited by 33
Isolation of Exosomes and Microvesicles from Cell Culture Systems to Study Prion Transmission
Leblanc, P., Arellano-Anaya, Z. E., Bernard, E., Gallay, L., Provansal, M., Lehmann, S., Schaeffer, L., Raposo, G., & Vilette, D. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6728-5_11 · Cited by 35
PrP interactions with nucleic acids and glycosaminoglycans in function and disease
Jerson, L. S. (2009) · Frontiers in bioscience · doi:10.2741/3611 · Cited by 34
“Over the years, many functions have been assigned to PrP, including immune regulation, signal transduction, copper metabolism, nucleic acid processing, synaptic transmission, protection, and induction of apoptosis (26-28).”
BackgroundPrion proteins: a biological role beyond prion diseases
Hu, W., Rosenberg, R. N., & Stüve, O. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00868.x · Cited by 38
“Prion infections cause characteristic lesions in the central nervous system (CNS) with spongiform vacuolation, neuronal cell loss, microglial activation and astrocytes proliferation (18).”
BackgroundRothwell, S. W., Sawyer, E. S., Dorsey, J., Flournoy, W. S., Settle, T., Simpson, D. J. W., Cadd, G., Janmey, P. A., White, C. E., & Szabo, K. A. (2009) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-009-3769-2 · Cited by 32
“Even non-human, mammalian proteins carry the risk of transmission of diseases such as bovine spongiform encephalopathy (Mad Cow disease) [5, 6].”
Brenner, S. R., & Brown, P. W. (2009) · Neurology · doi:10.1212/01.wnl.0000344245.13952.2d · Cited by 31
Role of proteolytic activation of protein kinase Cδ in the pathogenesis of prion disease
Harischandra, D. S., Kondru, N. C., Martin, D. P., Kanthasamy, A., Jin, H., Anantharam, V., & Kanthasamy, A. G. (2014) · Prion · doi:10.4161/pri.28369 · Cited by 31
Decreased CSF Transferrin in sCJD: A Potential Pre-Mortem Diagnostic Test for Prion Disorders
Singh, A., Beveridge, A. J., & Singh, N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016804 · Cited by 27
“protein (PrP) to a b-sheet rich pathogenic conformation called PrPscrapie (PrP) [1,2].”
BackgroundAlbanese, V., Lawson, V., Hill, A. F., Cappai, R., Guardo, G. D., Staikopoulos, V., Thacker, M., Furness, J. B., & Chiocchetti, R. (2008) · Autonomic Neuroscience · doi:10.1016/j.autneu.2008.01.008 · Cited by 27
Normal prion protein trafficking in cultured human erythroblasts
Griffiths, R. E., Heesom, K. J., & Anstee, D. J. (2007) · Blood · doi:10.1182/blood-2007-04-085183 · Cited by 30
Kim, Y., & Jeong, B. (2018) · Journal of Dairy Research · doi:10.1017/s0022029917000814 · Cited by 24
“BSE shares common features with Creutzfeldt–Jakob disease (CJD) showing scrapie like spongiform vacuolation of brain tissue and accumulation of the scrapie form of prion protein, PrPSc (Wood et al. 1997; Aguzzi & Heikenwalder, 2006).”
BackgroundMapping the interaction site of prion protein and Sho
Jiayu, W., Zhu, H., Ming, X., Xiong, W., Songbo, W., Bocui, S., Wensen, L., Li, J., Keying, M., Li, Z., et al. (2009) · Molecular Biology Reports · doi:10.1007/s11033-009-9722-0 · Cited by 24
“nantly expressed in cells of the central nervous system (CNS) and several other cell types [10].”
BackgroundGene expression profiling of mesenteric lymph nodes from sheep with natural scrapie
Filali, H., Martín‐Burriel, I., Harders, F., Varona, L., Hedman, C., Mediano, D. R., Monzón, M., Bossers, A., Badiola, J. J., & Bolea, R. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-59 · Cited by 23
“TSEs generally involve long incubation periods, which in humans can span several decades [1].”
BackgroundCells and prions: A license to replicate
Nuvolone, M., Aguzzi, A., & Heikenwälder, M. F. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.06.014 · Cited by 29
“prion tropism to organs hitherto believed prion-free [17,28,31].”
BackgroundSelf-citationXanthopoulos, K., Lagoudaki, R., Kontana, A., Kyratsous, C. A., Panagiotidis, C. Α., Grigoriadis, N., Yiangou, M., & Sklaviadis, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059143 · Cited by 22
“the lymphatic system ii) migrates through the peripheral to the central nervous system and eventually iii) from the central nervous system back to peripheral sites [7].”
BackgroundThe Effects of Immune System Modulation on Prion Disease Susceptibility and Pathogenesis
Mabbott, N. A., Bradford, B. M., Pal, R., Young, R. A., & Donaldson, D. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197299 · Cited by 22
Paradoxical Role of Prion Protein Aggregates in Redox-Iron Induced Toxicity
Das, D., Luo, X., Singh, A., Gu, Y., Ghosh, S. K., Mukhopadhyay, C. K., Chen, S. G., Sy, M., Kong, Q., & Singh, N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011420 · Cited by 21
“by a stochastic event. Sporadic Creutzfeldt-Jakob disease (sCJD) is a typical example”
BackgroundMeloni, G., Crameri, A., Fritz, G., Davies, P., Brown, D. R., Kroneck, P. M. H., & Vašák, M. (2012) · ChemBioChem · doi:10.1002/cbic.201200198 · Cited by 23
Preclinical Deposition of Pathological Prion Protein in Muscle of Experimentally Infected Primates
Krasemann, S., Neumann, M., Geissen, M., Bodemer, W., Kaup, F., Schulz‐Schaeffer, W., Morel, N., Aguzzi, A., & Glatzel, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013906 · Cited by 21
“The peripheral distribution of PrP has been well characterized in rodent models of prion diseases [32,33].”
BackgroundSelf-citationLevavasseur, E., Metharom, P., Dorban, G., Nakano, H., Kakiuchi, T., Carnaud, C., Sarradin, P., & Aucouturier, P. (2007) · Journal of General Virology · doi:10.1099/vir.0.82816-0 · Cited by 21
β-sheet constitution of prion proteins
Ji, H., & Zhang, H. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.12.002 · Cited by 21
Smith, M. C., & David M. Sherman DVM, M. (2009) · Wiley eBooks · doi:10.1002/9780813818825.ch5 · Cited by 22
Differential expression and protein distribution of Bax in natural scrapie.
Lyahyai, J., Bolea, R., Serrano, C., Vidal, E., Pumarola, M., Badiola, J., Zaragoza, P., & Martín-Burriel, I. (2007) · Brain Research · doi:10.1016/j.brainres.2007.08.085 · Cited by 17
Neuroinflammatory changes increase the impact of stressors on neuronal function
Piazza, A., & Lynch, M. A. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370303 · Cited by 20
Mori, J. J., Rivera, N. A., NOVAKOFSKI, J. E., & Mateus‐Pinilla, N. E. (2024) · Prion · doi:10.1080/19336896.2024.2343220 · Cited by 19
Martin, D. P., Anantharam, V., Jin, H., Witte, T. M., Houk, R. S., Kanthasamy, A., & Kanthasamy, A. G. (2011) · NeuroToxicology · doi:10.1016/j.neuro.2011.07.008 · Cited by 21
“The major neurological symptoms of TSE are extrapyramidal motor signs, including tremors, postural instability, ataxia, and myoclonus (Aguzzi and Heikenwalder, 2006; Brandner, 2003; Brown, 2002; Tatzelt and Schatzl, 2007).”
BackgroundMarruchella, G., Ligios, C., Albanese, V., Cancedda, M. G., Madau, L., Lalatta‐Costerbosa, G., Mazzoni, M., Clavenzani, P., Chiocchetti, R., Sarli, G., et al. (2007) · Journal of General Virology · doi:10.1099/vir.0.82907-0 · Cited by 19
“…G 2007 SGM Printed in Great Britain 2899 Downloaded from www.microbiologyresearch.org by IP: 54.70.40.11 On: Sun, 02 Jun 2019 01:20:40 of neuroinvasion for prions, which may subsequently gain access to the CNS through sympathetic and parasympathetic efferent fibres (Aguzzi & Heikenwalder, 2006).”
BackgroundSelf-citationBlinov, N., Dorosh, L., Wishart, D. S., & Kovalenko, A. (2011) · Molecular Simulation · doi:10.1080/08927022.2010.544306 · Cited by 18
“According to the ‘protein-only’ hypothesis [22], PrP (also known as prion, or proteinaceous infectious particle) is an infectious agent responsible for many neurodegenerative diseases, including scrapie in sheep, mad cow disease of cattle, cervid chronic wasting disease and Creutzfeldt–Jakob disease in humans [22,24,2…”
BackgroundAntiprion Prophylaxis by Gene Transfer of a Soluble Prion Antagonist
Genoud, N., Ott, D., Braun, N., Prinz, M., Schwarz, P., Suter, U., Trono, D., & Aguzzi, A. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070836 · Cited by 20
“26–28 This may also explain faster onset of disease seen for the groups treated with the same lentivirus at 30 dpi compared to 121 dpi.”
ResultSelf-citationIsrael's population: the challenge of pluralism.
Friedlander, D., & Goldscheider, C. (1984) · PubMed · Cited by 17
AUTONOMIC FAILURE IN NEURODEGENERATIVE DISORDERS
Kaufmann, H., & Goldstein, D. S. (2007) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000299968.51137.e4 · Cited by 18
Ubiquitin Ligase gp78 Targets Unglycosylated Prion Protein PrP for Ubiquitylation and Degradation
Shao, J., Choe, V., Cheng, H., Tsai, Y. C., Weissman, A. M., Luo, S., & Rao, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092290 · Cited by 16
“Structural analysis indicates that normal PrP contains a flexible N-terminal region (amino acids 23–124) and a folded C-terminal domain with three a-helices (amino acids 144–156, 172–193, 200–227), which is key to prion formation and pathogenesis [13,24].”
BackgroundInfluential
Metadata
- Authors
- Aguzzi, A., & Heikenwalder, M.
- Affiliations
- University Hospital Zurich (CH)
- Corresponding author
- Aguzzi, Adriano
- ORCID
- Aguzzi, Adriano
- Venue
- Nature Reviews Microbiology
- Published
- 2006-10
- Volume
- 4
- Issue
- 10
- Pages
- 765-775
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W2081750840
- Cited by
- 207
- References
- 163
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 7 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 11 · 2017: 9 · 2016: 7 · 2015: 5 · 2014: 9 · 2013: 11 · 2012: 11
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- prion disease, prion pathogenesis, immune system, prion replication, neurodegeneration, secondary lymphoid organs, chronic inflammation, prion protein conformation
- MeSH terms
- Animals, Humans, Ruminants, Prion Diseases, PrPSc Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.